title: The tumor suppressive effect of angiotensin II type 1 receptor antagonist in a murine osteosarcoma model.
abstract: BACKGROUND
  Angiogenesis is involved in the growth and metastasis of most solid tumors. Several reports have demonstrated that angiotensin II stimulates growth and migration of certain cancer cell lines and induces angiogenesis through up-regulation of vascular endothelial growth factor. This study examined whether an angiotensin II type 1 receptor (AT1R) antagonist (CV11974) inhibits osteosarcoma progression and distant metastasis.
  
  
  METHODS
  Osteosarcoma (LM8) was transplanted into subcutaneous dorsal tissue of C3H mice. The mice were administered CV11974 daily by intraperitoneal injections at 0.1 mg/kg, 1 mg/kg, or 10 mg/kg, or saline for 28 days.
  
  
  RESULTS
  Subcutaneous tumor size was smaller in the CV11974 treatment groups than in the control group. Lung and liver metastases were significantly reduced in the CV11974 treatment groups when compared with the control group.
  
  
  CONCLUSIONS
  CV11974 is widely used to treat hypertension clinically and therefore may be a novel antiangiogenic therapy for osteosarcoma through blocking AT1R-mediated signaling.
authors.affiliation: Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya. Japan. mjwasa@gb3.so-net.ne.jp
authors.forename: Junji
authors.initials: J
authors.lastname: Wasa
authors.forename: Hideshi
authors.initials: H
authors.lastname: Sugiura
authors.forename: Eiji
authors.initials: E
authors.lastname: Kozawa
authors.forename: Keishi
authors.initials: K
authors.lastname: Kohyama
authors.forename: Kenji
authors.initials: K
authors.lastname: Yamada
authors.forename: Osamu
authors.initials: O
authors.lastname: Taguchi
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001562:Benzimidazoles / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D015153:Blotting, Western; D001859:Bone Neoplasms / Q000098:blood supply / Q000473:pathology / Q000517:prevention & control*; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D008113:Liver Neoplasms / Q000098:blood supply / Q000517:prevention & control* / Q000556:secondary; D008175:Lung Neoplasms / Q000098:blood supply / Q000517:prevention & control* / Q000556:secondary; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D012516:Osteosarcoma / Q000098:blood supply / Q000517:prevention & control* / Q000556:secondary; D012333:RNA, Messenger / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013777:Tetrazoles / Q000627:therapeutic use*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D012333:RNA, Messenger; D013777:Tetrazoles; C081643:candesartan